Investor Relations
TSXV:NRX | OTCQB:NRXBF | FSE: J90
Transforming Regenerative Medicine
NurExone Biologic is developing exosome-based regenerative therapies for central nervous system injuries.
The Company’s lead therapeutic candidate, ExoPTEN, is being advanced for acute spinal cord injury, with optic nerve injury as an additional preclinical indication.
The investment case is supported by encouraging functional preclinical results, FDA and EMA Orphan Drug Designations for acute spinal cord injury, a completed pre-IND meeting with the FDA, and continued progress in manufacturing, product characterization and regulatory readiness.
In parallel, NurExone is developing exosome production, supply and selected commercial opportunities through Exo-Top, its wholly owned U.S. subsidiary.
Get Investor Updates
Financials & Filings
2025
2024
2023
2022
Latest News
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
Presentations
Latest
Presentation
One Pager
Optic Nerve
One Pager
Exo-Top
One Pager
ISEV TECH
Fact Sheet
AAEV
May 21, 2026
A Novel Exosome Platform at the Frontier of CNS Regeneration
By Robert Sassoon-WTR
Analyst Reports
2025
December 1, 2025
NRXBF: Tremendous Progress Made in Groundbreaking Treatment
By Zacks Small Cap Research
September 9, 2025
NRXBF: US Patent Awarded for Cell Technology
By Zacks Small Cap Research
August 11, 2025
NRXBF: Company Treatment Outperforms Industry Standard
By Zacks Small Cap Research
July 8, 2025
NRXBF: Test Results Show Spinal Injury Recovery
By Zacks Small Cap Research
May 27, 2025
NRXBF: Company Remains Disciplined Amid Progress
By Zacks Small Cap Research
April 10, 2025
NRXBF: Critical Year Starts with Company in Good Shape
By Zacks Small Cap Research
March 17, 2025
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
By Zacks Small Cap Research
2024
FRC provides fee-based coverage
December 11, 2024
Initiating Coverage: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment
By Fundamental Research Corp.
October 2, 2024
Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries
By Zacks Small Cap Research
